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Superparamagnetic iron oxide nanoparticles
stabilized by a poly(amidoamine)-rhenium
complex as potential theranostic probe†
Daniela Maggioni,*a,e Paolo Arosio,b,e Francesco Orsini,b,e Anna M. Ferretti,c
Tomas Orlando,d,e Amedea Manfredi,a Elisabetta Ranucci,a,e Paolo Ferruti,a,e
Giuseppe D’Alfonsoa,e and Alessandro Lascialfari*b,e
Three-component nanocomposites, constituted by a superparamagnetic iron oxide core coated with a
polymeric surfactant bearing tightly bound Re(CO)3 moieties, were prepared and fully characterized. The
water soluble and biocompatible surfactant was a linear poly(amidoamine) copolymer (PAA), containing
cysteamine pendants in the minority part (ISA23SH), able to coordinate Re(CO)3 fragments. For the
synthesis of the nanocomposites two methods were compared, involving either (i) peptization of bare
magnetite nanoparticles by interaction with the preformed ISA23SH-Re(CO)3 complex, or (ii) “one-pot”
synthesis of iron oxide nanoparticles in the presence of the ISA23SH copolymer, followed by complexa-
tion of Re to the SPIO@ISA23SH nanocomposite. Full characterization by TEM, DLS, TGA, SQUID, and
relaxometry showed that the second method gave better results. The magnetic cores had a roundish
shape, with low dispersion (mean diameter ca. 6 nm) and a tendency to form larger aggregates (detected
both by TEM and DLS), arising from multiple interactions of the polymeric coils. Aggregation did not
aﬀect the stability of the nano-suspension, found to be stable for many months without precipitate
formation. The SPIO@PAA-Re nanoparticles (NPs) showed superparamagnetic behaviour and nuclear
relaxivities similar or superior to commercial MRI contrast agents (CAs), which make them promising as
MRI “negative” CAs. The possibility to encapsulate 186/188Re isotopes (γ and β emitters) gives these novel
NPs the potential to behave as bimodal nanostructures devoted to theranostic applications.
1. Introduction
In the last decade, superparamagnetic iron oxide (SPIO) NPs
were intensively investigated as negative T2 contrast agents
for magnetic resonance imaging (MRI) and multimodal
imaging,1–17 and as agents for magnetic fluid hyperthermia
(MFH) treatment and drug delivery.18–25 This is evident from
the large number of SPIO NPs commercialized or under clini-
cal investigation (Feridex, Endorem, Resovist, Ferumoxtran-10,
Clariscan, AMI-121 and OMP) as contrast agents (CAs).26 The
key factor determining the SPIO NPs’ eﬃciency as CAs is to
possess large values of transverse nuclear relaxivity r2, which,
in turn, is governed by the size of the NPs, their aggregation
state, the diﬀusion time of the host solution molecules near
the NPs and, to a minor extent, by other parameters such as
the NP shape, the type of magnetic ion and the coating27,28
(for instance, it has been predicted that the maximum relaxiv-
ity for magnetite is reached for particles having a diameter
of 25 nm). It should be also remarked that clustering small
magnetic nanoparticles was shown to provide an eﬃcient
strategy for improving relaxivity without aﬀecting water
solubility.27,29
Despite the wide eﬀort of the scientific community, up to
now no eﬀective synthetic method for biocompatible NPs has
been shown to optimize all the above microscopic require-
ments for obtaining the highest relaxivity, keeping at the same
time additional functionalities suitable for e.g. γ- or β-radio-
emission (to be used in diagnostic SPECT and in radiotherapy,
respectively), luminescence, drug delivery or MFH.1–24
The most widely used method for the synthesis of iron
oxide based SPIO NPs consists of the co-precipitation of Fe3+
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and Fe2+ salts in basic aqueous solution, a major drawback of
this synthesis being the poorly achievable monodispersity. For
this reason many authors in the last decade investigated
alternative synthetic strategies,30–32 which, however, in many
cases require extensive post-synthesis treatments to impart
hydrophilicity to the NPs.
Actually, it should also be taken into account that for any
biomedical application, the nanoparticles should possess high
water solubility, biocompatibility and stability at physiological
pH. Water soluble polymers, such as dextran and its deriva-
tives, starch or polyethylene glycol, have been largely employed
for SPIO stabilization.3,25,33 The use of polymer surfactants
directly in the coprecipitation step has been shown to prevent
aggregation and achieve a better control of the NP size, as was
recently reported.34 On the other hand, poly(amidoamine)s
(PAAs) are a family of water soluble polymers which possess
many favourable properties for biomedical uses:35 they are bio-
degradable and biocompatible. Moreover, some PAAs, such as
the amphoteric but predominantly anionic one named ISA23,
when injected in the bloodstream, exhibit a “stealth-like” be-
haviour; that is, they circulate for a long time without preferen-
tially localizing in the liver and can be used as carriers for
drugs or, if properly labeled, as diagnostic probes.36 The
repeating unit of ISA23 contains a carboxyl group and, there-
fore, holds great potential for coating and clustering SPIO
cores, since the carboxyl group is one of the most widely used
binding units for surface-capping iron oxide NPs.37–42
In this work we report on the synthesis, by two diﬀerent
routes, and the full characterization of Fe3O4–ISA23SH-Re
nanocomposites constituted by a magnetic iron oxide (Fe3O4)
core, covered by a copolymer strictly related to ISA23 (namely
ISA23SH, Chart 1a),43 which contains a minor fraction
(ca. 10%) of repeating units bearing a cysteamine pendant,
able to firmly bind to a “Re(CO)3” fragment
44 (the resulting
stable polymer complex is ISA23SH-Re, Chart 1b).
The above SPIO@PAA-Re nanocomposite models a poten-
tial diagnostic radiopharmaceutical, since: (a) rhenium has
two radioisotopes, 186Re and 188Re, which are both γ and
β emitters, with lifetimes and energies compatible with
applications in diagnosis (γ) and therapy (β)45 (the use of
Re(CO)3 units as a rhenium source is advantageous, because the
preparation of the starting material [Re(CO)3(H2O)3]
+ marked
with 188Re is well established);46–48 (b) the SPIO core allows the
NPs to act as contrast agents for MRI. As a consequence, the
SPIO@PAA-Re nanocomposites herein described are potential
dual probes49 for theranostic applications. It is worth mention-
ing that in vitro and in vivo biological studies using
ISA23SH-Re containing cold rhenium isotopes revealed neither
hemolytic activity, nor cytotoxic eﬀects on HeLa cells nor
apparent toxic eﬀects after injection in mice.44
2 Experimental
2.1 Reagents and materials
FeCl2·4H2O (Fluka), anhydrous FeCl3 (Merck), NaOH (32%,
Fluka), HCl (30%, Suprapur, Merck), and fetal bovine serum
(FBS, Sigma) were used as received. Ultrapure water (Milli-Q,
Millipore, resistivity 18 MΩ cm−2) was used for the preparation
of the aqueous solutions; it was previously deoxygenated by
several vacuum/N2 cycles just before use. The copolymer
ISA23SH10% (containing ca. 10% of the cysteamine bearing
repeating units, Mn = 14 000, Mw = 24 800, PD = 1.78) was syn-
thesized as previously reported.44 The ISA23SH-Re copolymer
was prepared by reacting ISA23SH with the precursor complex
[ fac-Re(CO)3(H2O)3](CF3SO3) for 30 min under microwave
(MW) activation at 80 °C, as previously reported.44 [ fac-Re-
(CO)3(H2O)3](CF3SO3) was synthesized according to literature
procedures,50 starting from Re2(CO)10 (Aldrich).
2.2 Synthesis of the Fe3O4–ISA23SH-Re nanocomposite by
peptization of Fe3O4 nanoparticles: SPIO@PAA-Re(1)
Magnetite nanoparticles were prepared by a slightly modified
Massart’s coprecipitation method,51 in aqueous medium from
a solution of Fe(III) and Fe(II) chloride salts. FeCl3 (38.9 mg,
0.24 mmol) and FeCl2·4H2O (24.3 mg, 0.121 mmol) were dis-
solved in 400 μL of 0.32 M HCl, and added to 3.0 mL of a
1.5 M NaOH solution, under N2 bubbling to favour the for-
mation of small nanoparticles,3 resulting in the instantaneous
formation of a dark brown magnetic precipitate. The precipi-
tate was decanted with an external magnet and washed several
times with water until neutral pH, and then it was treated with
a water solution of the ISA23SH-Re copolymer containing 0.5
equivalent of Re(CO)3 moieties with respect to the SH groups
(112.9 mg in 1.2 mL, 0.3 M with respect to the COOH groups),
and sonicated for 2 h at 60 °C. A brown homogeneous suspen-
sion was formed without a visible precipitate. The sample of
SPIO@PAA(1) thus obtained was dialyzed for three days
against deoxygenated water under N2, using a membrane cut-
oﬀ of 50 kDa, and finally lyophilized.
2.3 One-pot synthesis of Fe3O4 nanoparticles coated with
ISA23SH: SPIO@PAA(2)
A sample of the copolymer ISA23SH10% (56.2 mg, 0.18 mmol
with respect to the repeating monomer) was dissolved in
90 mL water, in a three necked round bottom flask equipped
with a mechanical stirrer, and the pH was adjusted to 2 by
Chart 1 Schematic drawing of (a) the ISA23SH10% copolymer, in which
the majority fraction (0.9) is constituted by the same repeating unit of
the ISA23 homopolymer; (b) the ISA23SH-Re complex, in which the
sixth coordination position around Re (marked with X) is mainly occu-
pied by a carboxylate group of the polymer backbone.44
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addition of HCl. Then, 12.2 mg of FeCl2·4H2O (0.06 mmol)
and 19.5 mg of anhydrous FeCl3 (0.12 mmol) were added to
the acidic solution and stirred for 10 min at 300 rpm. The
stirring rate was increased to 500 rpm, and fast injection of
400 μL of 32% NaOH caused a sudden change of the pH (from
2 to 11.5) and of the colour (from colourless to brownish). The
clear suspension was stirred at room temperature for 1 h, and
then the pH was lowered to neutrality by addition of HCl. The
suspension was dialyzed against water under N2 with a mem-
brane cut-oﬀ of 50 kDa for three days and finally lyophilized.
The lyophilized samples were stored at 4 °C and found to be
stable over a period of more than 8 months.
2.4 Complexation of fac-Re(CO)3 groups to the
Fe3O4-ISA23SH nanocomposites: SPIO@PAA-Re(2)
A clear suspension of the SPIO@PAA(2) (23 mL) at pH 5.1 was
treated with 47.2 μL of a 0.1 M solution of [Re(CO)3(H2O)3]-
(CF3SO3), corresponding to 1 equivalent with respect to the SH
groups. The mixture was heated by MW irradiation for 30 min
at 50 °C. The sample was ultracentrifuged to eliminate
unreacted Re starting material (twice, at 7000 rpm, 35 min,
20 °C using an Amicon Ultra Centrifugal Filter (Millipore) with
a membrane cutoﬀ of 3000 Da). The occurrence of the reaction
was monitored by IR spectra of the retained and filtrate frac-
tions (Bruker Vector22 FTIR instrument, 0.1 mm CaF2 cells):
νCO in the retained fractions: 2019s, 1902vs cm
−1; in the filtrate
2037s, 1916vs cm−1.
2.5 Stability test
The stability of SPIO@PAA-Re(2) nanocomposites was checked
in a saline solution (0.150 M NaCl) containing 20 equivalents
of the ubiquitous amino acid cysteine. After 24 h at 37 °C
neither precipitate formation was observed, nor changes of the
νCO IR bands of the retained portion after ultracentrifugation
(twice at 7000 rpm, 35 min, 20 °C using an Amicon Ultra Cen-
trifugal Filter (Millipore) with 3000 Da membrane cutoﬀ ) were
observed. Moreover the filtrate portions did not show any
νCO absorption. A further stability test was performed by moni-
toring by DLS the size of SPIO@PAA-Re(2) nanoparticles, in a
suspension added with 10% (v/v) FBS, over 24 h after serum
addition. The sample of SPIO@PAA-Re(2) used for the test
was suspended for 9 months without significant signs of
aggregation.
2.6 Thermogravimetric and elemental analyses
TGA measurements were carried out with a heating rate of
3 °C min−1 in the temperature range from 50 °C to 700 °C,
under air flux, on 10–20 mg of lyophilized samples, using a
Perkin Elmer TGA7HT instrument. The Fe content of the nano-
composites was determined by atomic absorption analyses on
an AAnalyst 100 PerkinElmer instrument. The Re and S
content of SPIO@PAA-Re(2) was determined by ICP-OES (ICAP
6300, Thermo Electron) on a sample (4.3 mg) dissolved in
1 mL milli-Q water, 0.5 mL 30% HCl (Suprapur) and 0.5 mL
65% HNO3 (Suprapur), digested overnight at room tempera-
ture. The S content: calculated 2.72 ppm (on the basis of
1H NMR); measured 2.84 ± 0.04 ppm. Measured Re content
2.49 ± 0.05 ppm (corresponding to a Re–S ratio = 0.16).
2.7 Dynamic light scattering (DLS) and ζ-potential
measurements
DLS and ζ-potential measurements were carried out on a Zeta-
sizer Nano ZS instrument (Malvern Instruments Corp.,
Malvern, Worcestershire, UK) at a wavelength of 633 nm with a
solid state He–Ne laser at a scattering angle of 173°, at 298 K
on diluted samples at pH 7. Each hydrodynamic diameter was
averaged from at least three measurements. Standard
deviations of the diﬀusion coeﬃcients were obtained by the
non-linear fitting of the correlation function G(t ) = 0.15
P
i
AieDiqt
 2
, where q is the wave vector and is equal to 4πn/λ
sin(θ/2), λ is the wavelength of the incident light (633 nm), θ is
the detecting angle (173°), and n is the refracting index of the
solution approximated to that of the pure solvent (1.33).52 The
standard deviations of the hydrodynamic diameters were com-
puted accordingly using the Origin© data analysis software
package. From the diﬀusion coeﬃcients, the hydrodynamic
diameters, dH, were obtained through the Stokes–Einstein
equation, Dt = (kT )/cπηrH, where k is Boltzmann’s constant, T
is the absolute temperature, η is the solution viscosity (approxi-
mated to that of pure water), and c is a factor depending on
the size of the diﬀusing species with values ranging between 4
(slip boundary conditions) and 6 (stick boundary conditions).53
2.8 Transmission electron microscopy (TEM)
TEM images were recorded using a Zeiss LIBRA EFTEM FEG
TEM, operating at 200 kV and equipped with an in-column
omega filter for energy selective imaging and diﬀraction.
Samples were prepared by drop drying a water diluted sus-
pension of the studied samples. The average diameter and
size distribution of the studied samples were determined by
statistical analysis over 500–600 NPs. Images were processed by
means of the iTEM TEM Imaging Platform software (Olympus).
2.9 Magnetic characterization, relaxivity and MRI
measurements
Magnetic measurements were carried out on powders and
suspensions using a Quantum Design SQUID MPMS
XL-7 magnetometer. The zero field-cooled and field-cooled
(ZFC/FC) curves were obtained with an applied magnetic field
of 50 Oe in the temperature range 2–300 K, while the field
dependent magnetization measurements were recorded in the
range of ±5 T at both 2 K and room temperature.
The 1H NMR relaxometry characterization (NMR-dispersion
profile) was performed at physiological temperature (37 °C)
and room temperature by measuring the longitudinal and
transverse nuclear relaxation times T1 and T2, in the frequency
range 10 kHz–240 MHz. It should be noted that the measure-
ments at room and physiological temperatures gave the same
results within 10% (corresponding to viscosity change of
water). The range of frequency ν has been chosen in order to
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cover the most widely used clinical fields, i.e. 0.2 T
(ca. 8.5 MHz), 0.5 T (ca. 21 MHz) and 1.5 T (ca. 64 MHz), and
to study the mechanisms that led to the nuclear relaxation,
through the analysis of the curves of r1 and r2 vs. ν (NMRD pro-
files). The NMR signal detection and generation was obtained
with a Smartracer® Fast-Field-Cycling relaxometer (Stelar,
Mede, Italy) in the range 10 kHz–10 MHz, with a Stelar Spin-
master spectrometer for 10 MHz–60 MHz and with a Tecmag
Apollo spectrometer equipped with an Oxford TH9/88/15
superconductor, working in the range 100–240 MHz. In the
second and the third case, standard radio frequency excitation
sequences were used for T1 and T2 measurements, respectively
saturation-recovery for T1, Carr Purcell Meiboom Gill (CPMG)
for T2. To determine the eﬃciency of MRI contrast agents, we
calculated the longitudinal (r1) and transverse (r2) nuclear
relaxivities, defined as the increase of relaxation rates of the
solvent induced by 1 mmol L−1 of iron:
ri ¼ ½ð1=TiÞmeas  ð1=TiÞdia=CFe i ¼ 1; 2 ð1Þ
where (1/Ti)meas is the relaxation rate measured for a sample of
iron concentration CFe (mmol L
−1), and (1/Ti)dia represents the
diamagnetic contribution to the nuclear relaxation rate of the
host solution.
In vitro MRI experiments were performed on vials contain-
ing SPIO solutions at 8.5 MHz using an Artoscan Imager by
Esaote SpA. The employed pulse sequence was a high resolu-
tion spin echo sequence with TR/TE/NEX = 500 ms/18 ms/2,
matrix = 256 × 192, FOV = 180 × 180 for the T1-weighted image,
and with TR/TE/NEX = 1000 ms/80 ms/2, matrix = 256 × 192,
FOV = 180 × 180 for the T2-weighted image. Here TE is the
echo time, TR the repetition time, NEX the number of averages
and FOV the field of view.
3. Results and discussion
3.1 Synthesis of the SPIO@PAA-Re nanocomposites
For the synthesis of the nanocomposites two methods were
tested. The first one (1 in Scheme 1) involved two steps: bare
magnetite nanoparticles were prepared by coprecipitation51
and then peptized by interaction with the water-soluble PAA
copolymer ISA23SH-Re (shown in Chart 1b). The rhenium
loading of the copolymer corresponded to about one-half of
the copolymer SH groups. The IR spectra in the region of the
ν(CO) absorptions (Fig. S1†) showed that the interaction with
iron oxide did not change the rhenium coordination environ-
ment. In particular the position of the bands was in agreement
with the presence of a carboxylate group in the sixth coordi-
nation position of Chart 1b, as in the starting ISA23SH-Re
copolymer.44
The peptization of the precipitated magnetite nanoparticles
was eﬀective when performed at pH ca. 3, to favour electro-
static interactions between the COOH groups of the polymer
and iron oxide NPs. Indeed, at this pH the surface charge of
the NPs is highly positive,54 while the carboxyl groups of the
polymer, which are strongly acidic, are deprotonated.55 The
peptization process required heating and sonicating (60 °C,
2 h), and produced clear brown suspensions of the nano-
composite, labelled as SPIO@PAA-Re(1) in Scheme 1, which
were purified by dialysis (3 days against water) and lyophilized.
Thermogravimetric analysis (TGA, Fig. S2†) showed that
ca. 20% of the weight was attributable to the iron oxide core
(corresponding to ca. 14 wt% of Fe), in good agreement with
the analysis by atomic absorption spectroscopy (13 wt% of Fe).
This implies the presence of about 150 polymer coils (Mn =
1.4 × 104 Da) per nanoparticle (on the basis of the mean NP
size indicated by TEM analysis, see below).
The light-brown lyophilized solid easily dissolved in water,
aﬀording suspensions stable over a period of months, without
separation of the precipitate. The covering of the nanoparticles
by the PAA was further confirmed by ζ potential measure-
ments, which showed the isoelectric point at pH ca. 5, roughly
corresponding to that of ISA23,55 but well below the value
reported for bare magnetite NPs (pH 8).54 In general the trend
of ζ potential values at variable pH (Fig. 1) was very similar to
that measured for ISA23SH alone, which is known to spon-
taneously self-assemble in spherical nanosized aggregates
(dH ca. 10 nm).
44 The ζ potential value at neutral pH was far
enough from zero to prefigure stability of the suspensions
under physiological conditions.
However, the physical characterization (see the next para-
graph) showed that the magnetic properties were negatively
aﬀected by the relatively high polydispersity of the sample.
Moreover, the time-consuming purification by dialysis of the
SPIO@PAA-Re(1) nanocomposite was poorly compatible with
the relatively short lifetimes of the radioactive Re isotopes
(17 h 188Re, 88 h 186Re).
Therefore, an alternative synthetic approach was investi-
gated which involved a diﬀerent kind of two-step procedure
with respect to method 1 (route 2 in Scheme 1). At first a
SPIO@PAA nanocomposite (devoid of rhenium) was prepared,
and then, after proper extensive purification, it was conjugated
Scheme 1 The synthetic routes used in this work for preparing the
SPIO@PAA nanomaterials, containing iron oxide nanocrystals coated
with the poly(amido)-amine (PAA) ISA23SH, decorated with Re(CO)3
units.
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to rhenium by a fast reaction. The nanocomposite produced in
the first step, labelled as SPIO@PAA(2) in Scheme 1, was
obtained by a one-pot reaction involving NaOH addition to an
acidic solution containing Fe(II), Fe(III) and ISA23SH at room
temperature under vigorous mechanical stirring with no need
for heating or sonicating. The resulting clear suspension
showed high stability, even in the presence of the magnetic
field, and favourable morphological and magnetic properties
of the nanocomposites (see below). The presence of the
polymer during the nanoparticle formation has therefore
a beneficial eﬀect on the morphology of the product, as
previously reported using diﬀerent stabilizing polymers.34
For the subsequent conjugation of rhenium, microwave
irradiation was used, since it is known that this heating source
can promote and accelerate many kinds of reactions.56 In spite
of the high dilution, the low temperature and the very short
reaction time employed (2 × 10−4 M with respect to Re, 55 °C,
0.5 h, respectively), a satisfactory amount of rhenium was cap-
tured by the nanoparticles, corresponding to about one-sixth
of the cysteamine pendants of ISA23SH (on average 0.75
rhenium atom per polymer coil and then more than
100 rhenium atoms per NP, according to the ICP analysis of
the rhenium content). Such a rhenium loading is adequate,
since very low dosages are usually necessary for radioemitter
drugs,45,57 whereas high quantities of SPIO NPs have to be
administered to provide eﬀective contrast.58 IR spectroscopy of
these SPIO@PAA-Re(2) NPs confirmed the uptake of Re(CO)3
groups, showing ν(CO) absorption in the fraction retained after
ultracentrifugation. The position of these bands (2019s,
1902vs, br cm−1, Fig. S3†) was diﬀerent with respect to the
nanocomposite SPIO@PAA-Re(1), suggesting the presence of a
water molecule in the sixth coordination position of the
Re(CO)3–cysteamine complex.
44 Indeed, in this case the
carboxylate groups of the polymer are supposed to be already
interacting with the NP surface in the SPIO@PAA(2) starting
material, and are then unable to coordinate to the metal.
The thermal profile by TGA analysis (Fig. S2†) was slightly
diﬀerent with respect to that of NPs obtained by peptization,
but the amount of iron oxide was strictly comparable (23%).
Moreover, no significant change after rhenium addition was
observed.
It is worth pointing out that magnetite cores are produced
by the coprecipitation method, but partial subsequent oxi-
dation (in spite of the use of a nitrogen atmosphere for NP
handling) might produce diﬀerent iron oxide nanophases.
Among these, maghemite NPs (γ-Fe2O3) have magnetic pro-
perties comparable with magnetite and can hardly be diﬀeren-
tiated from magnetite NPs by diﬀraction experiments. The
electron diﬀraction pattern reported below showed a pattern
compatible with these two phases only, which throughout this
paper will be referred to as iron oxide.
3.2. Size and morphological characterization
The SPIO@PAA-Re(1) nanocomposite was morphologically
characterized using a transmission electron microscope (TEM,
Fig. 2a). The nanocrystal shape was irregular, varying from
quasi-spherical to strongly elongated. An estimation of the
mean dimension was done, thus obtaining an equivalent
mean diameter = 7.3 ± 3.1 nm and a distribution median =
6.9 nm (Fig. 2b). The diﬀerence between the mean and
Fig. 1 ζ Potential versus pH curves recorded for SPIO@PAA-Re(1) (■)
and for the copolymer ISA23SH alone ( ).
Fig. 2 (a) TEM images of SPIO@PAA-Re(1) prepared by peptization (the
white arrow shows the aggregates), (b) histogram of size distribution
and (c) electron diﬀraction pattern.
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median values highlights the asymmetry and the amplitude of
size distribution. The polymer surrounding the NPs was not
detectable in these TEM images, which however showed the
presence of large aggregates (highlighted by arrows in Fig. 2a).
This accounts for the results of the DLS analysis of the same
sample, performed at pH 7, which showed the presence of
highly polydispersed nanoaggregates, much larger than the
single SPIO NPs detected by TEM. The distribution by
numbers stated that the most relevant component was rep-
resented by NPs with hydrodynamic diameter dH centred
at 104 nm.
At variance with this, the TEM images of the SPIO@PAA(2)
sample (Fig. 3a) revealed that the magnetic cores had a round-
ish shape with a low dispersion, mean diameter = 6.6 ± 1.8 nm
and distribution median = 6.6 nm (Fig. 3b), which stress the
sharper and more symmetric distribution of NP dimensions,
with respect to SPIO@PAA-Re(1). It is worth noting the pres-
ence of small and relatively regular aggregates, having a length
of 40–60 nm and a width of 10–30 nm, surrounded by a thin
layer of PAA, well visible like a halo in TEM image (Fig. 4). This
TEM information is qualitative, but well agrees with DLS
data.59 Indeed the analysis of the dialyzed suspension of
SPIO@PAA(2) showed a size distribution (numbers) centred at
ca. 70 nm (Fig. S4†), which remained constant over several
months. The analysis of the correlograms by a non-linear bi-
exponential fitting estimated two populations centred at ca. 70
and 170 nm, with the first one being largely dominant (ratio
1000 : 1), in line with the numbers distribution size analysis.
The electron diﬀraction (ED) analysis (Fig. 2c and 3c)
revealed the typical diﬀraction pattern of magnetite/
maghemite crystals. The rings were easily assigned to the low
index crystal planes. They were sharper for SPIO@PAA(2) than
for SPIO@PAA-Re(1), because of the smaller size distribution,
and were slightly blurry, because of the presence of PAA sur-
rounding nanocrystals, as the TEM images pointed out.
The comparison of TEM images acquired before and after
the complexation of fac-Re(CO)3 moieties on SPIO@PAA(2)
(Fig. S5†) showed that shape, size and size distributions were
conserved after microwave irradiation at 50 °C for 30 min for
rhenium conjugation. Moreover, the powder diﬀraction
pattern confirmed that the spinel crystal structure of iron
oxide nanoparticles was preserved. The only significant eﬀect
was a modification in the aggregation of the nanocomposites,
since after the complexion reaction, aggregates were no longer
clearly detectable in TEM images. In agreement with this, DLS
showed a decrease in the size, which after MW irradiation was
centred at ca. 25 nm (according to distribution by numbers,
Fig. S6†). However, this did not aﬀect the magnetic properties
(see the next paragraph).
The formation of aggregates, revealed both by DLS and
TEM, likely results not only from non-bonding interactions
between polymer coils coating diﬀerent cores, but also
from interactions of single polymer coils with the surfaces
of diﬀerent iron oxide NPs (each coil bearing dozens of
carboxylate groups regularly distributed along its chain). Such
Fig. 3 (a) TEM images of SPIO@PAA(2) prepared by the “one-pot” syn-
thesis, (b) histogram of size distribution and (c) electron diﬀraction
pattern.
Fig. 4 Magniﬁcation of a TEM image of SPIO@PAA(2) NPs. The black
arrow indicates the polymer presence.
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aggregation does not compromise the stability of the nano-
suspensions, since no precipitate formation was observed for
very long times.
3.3. Magnetic and relaxivity properties
Fig. 5(a) shows the zero-field-cooled (ZFC) and field-cooled
(FC) magnetization of a powder sample of SPIO@PAA-Re(1).
The ZFC magnetization curve increases with temperature,
reaching a maximum at temperatures T = 75–85 K, which can
be assumed, as a first approximation, to coincide with the
blocking temperature TB. The FC curve increases as the temp-
erature decreases and never reaches saturation at low tempera-
ture, suggesting that interparticle interactions do not
significantly aﬀect the relaxation dynamics. The ZFC and FC
curves start to diverge at a temperature far above the TB esti-
mated with the ZFC curve. This is due to relatively broad size
and shape distributions of the sample as observed in the TEM
micrographs. Indeed for this sample, according to the Néel
model, the transition from the blocked to the superparamag-
netic regime occurs at diﬀerent temperatures for diﬀerent par-
ticle sizes. The magnetization curve as a function of the field
in Fig. 5b shows an open hysteresis loop at 2 K with a coercive
field Hc = 480 Oe. The hysteresis curve is substantially satu-
rated at the highest applied field (>3 T).
On the other hand, magnetic measurements on a sample of
SPIO@PAA(2) confirmed the higher monodispersity of the
magnetic core, with respect to SPIO@PAA-Re(1), as indicated
by TEM micrographs. Indeed the ZFC–FC magnetization
curves reported in Fig. 5c show that their divergence occurs at
a temperature close to the blocking temperature TB (T = 50 K).
In addition a lower TB is indicative of a smaller nanoparticle
size as observed in TEM, while the increase of magnetization
in the FC curve at low temperature is probably due to paramag-
netic impurities. The field dependent magnetization curve for
SPIO@PAA(2) confirms that the sample is superparamagnetic
at room temperature with zero coercivity, whereas at 2 K an
open hysteresis loop is observed, Fig. 5d, with a coercive field
Hc = 270 Oe. The hysteresis curve is saturated at 4 T.
SPIO@PAA-Re(1) NPs were characterized by NMR relaxo-
metry and their r2 relaxivity, compared to the negative commercial
contrast agent Endorem®, is reported in Fig. 6a. r2(ν) Values
were higher than commercial compounds in the whole fre-
quency range and interestingly showed a continuous increase
at high frequencies (ν ≥ 10 MHz). The longitudinal nuclear
magnetic relaxation dispersion (NMRD) curve (r1 vs. ν)
obtained for the SPIO@PAA-Re(1) NPs (see Fig. S7†) displayed
a typical behaviour for a superparamagnetic CA: it stays flat for
low frequencies, and then reaches a maximum and finally
decreases rapidly at higher frequencies, showing a profile
Fig. 5 (a) ZFC and FC magnetization curves of SPIO@PAA-Re(1) at 50 Oe; (b) hysteresis cycle recorded at low temperature (2 K) for SPIO@PAA-
Re(1); inset: zoom of the hysteresis cycle at low ﬁelds; (c) ZFC and FC magnetization curves of SPIO@PAA(2) at 50 Oe; and (d) hysteresis cycle
recorded at low temperature (2 K) for SPIO@PAA(2); inset: zoom of the hysteresis cycle at low ﬁelds.
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qualitatively similar to Endorem®, except for a shift towards
lower frequencies and an increased height, of the peak. In the
case of SPIO@PAA(2) the NMRD longitudinal relaxivity curve
(r1 vs. ν), reported in Fig. 6b, follows the profile of Endorem®,
except for the height of the peak. In general the shape of the
r1(ν) NMRD curve can be explained through the known mecha-
nisms of nuclear longitudinal relaxation in superparamagnetic
particles.2,3,60,61 The mechanism dominating at low frequency
is the Néel relaxation, induced by the reversal of the magnetic
moment through the anisotropy energy barrier. The other
mechanism, predominating at higher frequencies, is the Curie
relaxation, ascribed to the progressive orientation of the mag-
netic moment with increasing the field. According to Lange-
vin’s law, this mechanism depends on the core size and
magnetization of the nanoparticles and on the temperature.
Curie’s mechanism is responsible for the maximum of r1(ν) at
higher frequencies and the frequency shift of the peak is
directly explained by the change in the nanoparticles size.
Therefore the diﬀerent position of r1 maxima for SPIO@
PAA-Re(1) and SPIO@PAA(2), see Fig. S7† and Fig. 6b, is corre-
lated to the diﬀerent NP sizes, as also evidenced by TEM and
magnetic measurements. Measurements on SPIO@PAA-Re(2)
NPs (Fig. 6b) at selected frequencies (in the range 1–42 MHz,
of interest for the chemico-physical properties of the sample
and clinical applications) demonstrated that the subsequent
conjugation of rhenium on SPIO@PAA(2) does not aﬀect the
mechanisms of longitudinal nuclear relaxation in the system.
In Fig. 6c the NMRD transverse relaxivity curve (r2 vs. ν) of
SPIO@PAA(2) is reported, together with the data for SPIO@
PAA-Re(2). Values similar to Endorem were found in the low
frequency region, while for ν > 10 MHz a clear enhancement of
r2 values was observed. The transverse nuclear relaxation rate
(1/T2) is partially described by an approximate heuristic model
in the framework of the so-called motional averaging regime
(MAR), in which the protons of water molecules surrounding
the material are sensitive to the magnetic dipolar field created
by the electronic magnetic moments.2,3 The model in the MAR
regime (valid when the Redfield condition is verified, i.e. ΔωτD
< 1) predicts that the transverse relaxation rate at high field is
described by the equation: R2 = 1/T2 = (16/45) fτD(Δω)2, where f
is the volume fraction occupied by the nanoparticles in the
suspension, Δω = γμ0MV/3 is the angular frequency shift experi-
enced by a proton at the equator of the particle, γ is the gyro-
magnetic factor of the proton, μ0 is the magnetic permeability
of vacuum, MV is the saturation magnetization divided by the
particle volume and τD = d
2/4D is the translational diﬀusion
time of the protons in the magnetic field inhomogeneities
created by the nanoparticles (D being the water translational
diﬀusion constant and d the particle diameter). Recently
Gossuin, Sandre et al.62 proposed a universal scaling law to
predict the eﬃciency of magnetic nanoparticles as T2-contrast
agents revising the model in the MAR regime. The authors pro-
posed to modify the r2 relaxivity, obtained within the MAR
regime, by means of the intra-aggregate volume fraction of
magnetic materials ϕintra to derive a corrected relaxivity r2′. In
this way the authors state that it is possible to properly
compare the obtained relaxation data of diﬀerent kinds of
nanoparticles “as if they were filling the same volume fraction
of suspensions of single USPIO nanoparticles”. Our data at a
fixed frequency (20 and 60 MHz, near clinical ones) follow this
model which, on the other hand, cannot describe the whole
Fig. 6 (a) Transverse r2 relaxivity in SPIO@PAA-Re(1) (star symbols), dis-
persed in ultrapure water. Data are compared with the ones measured
for the commercial compound Endorem® (black squares). (b) Longitudi-
nal r1 relaxivity and (c) transverse r2 relaxivity of SPIO@PAA(2) (open dia-
monds) and SPIO@PAA-Re(2) (grey circles) dispersed in water. Data are
compared with the ones measured for the commercial compound
Endorem® (black squares).
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transverse NMRD curve (r2 vs. ν) or explain the relaxation
mechanisms as a function of the applied magnetic field.
Nevertheless being the transverse relaxivity r2 the fundamental
parameter to test the MRI eﬃciency for a superparamagnetic
material, the reported experimental data demonstrate that our
nanoparticles act as promising negative contrast agents. The
lowering of r2 values for SPIO@PAA(2) (30–40%) with respect
to SPIO@PAA-Re(1) is probably due to the diﬀerent core size
and the diﬀerent aggregation of the two samples.
To get a confirmation of the contrast enhancement ability
of our SPIO@PAA(2) samples, MRI in vitro experiments
have been performed on a phantom composed of four vials
containing: a suspension of the SPIO@PAA(2) sample,
Magnevist® (positive or T1 relaxing commercial CA),
Endorem® (negative or T2 relaxing commercial CA) and ultra-
pure water. A standard high resolution spin echo sequence was
used to verify the MRI eﬃciency of SPIO@PAA(2) both as T1
and T2 relaxing agents. In Fig. 7a the T1-weighted image is
shown, where a mild ability of the sample to contrast the
image as a positive CA is evident. The T2-weighted image,
reported in Fig. 7b, is in good agreement with the measured r2
relaxivities at approximately 8 MHz, corresponding to our MRI
tomograph operating field (0.2 T). As can be seen from the
image, the solution containing SPIO@PAA(2) contrasts with
the image at the same quality level of the commercial CA, con-
firming the eﬃcacy of our material.
3.4 Preliminary stability test of SPIO@PAA-Re(2) under
physiological conditions
A preliminary stability assay mimicking physiological con-
ditions was performed on the most promising sample, i.e.
SPIO@PAA-Re(2), to test possible aggregation phenomena and
the stability of the binding of the rhenium moiety to the nano-
composite, in the presence of possible competitors. A suspen-
sion of the dialyzed nanocomposite was added with NaCl (up
to 0.15 M) and 20 equivalents (with respect to the rhenium
moieties) of a ubiquitous amino acid like cysteine, which
should be able to compete with the chelating pendant of the
polymer in the coordination of the metal centre. After 24 h at
37 °C no aggregation was observed; moreover, after ultracentri-
fugation no IR bands ascribable to carbonyl ligands were
observed in the filtrate, while the IR spectrum of the retained
portions was unchanged, indicating no detachment of
rhenium from the nanocomposite. The stability test was
repeated in the presence of 10% (v/v) fetal bovine serum. The
NP suspension remained clear over 24 h and DLS monitoring
(Fig. S8†) showed that the intensity peak remained centred at
about 100 nm, as before FBS addition.
4. Conclusions
An amphoteric PAA named ISA23SH (containing carboxyl and
ter-amine groups in each repeating unit and 10% units also
carrying one mercapto group) has been found to eﬀectively
stabilize iron oxide NPs, acting either post synthesis (peptiza-
tion) or simultaneously with the NP formation. In both cases,
very stable hybrid organic–inorganic nanocomposites have
been produced, in which small SPIO nanoparticles are coated
with a large excess of polymer coils decorated with a “Re(CO)3”
fragment. The one-pot synthetic route gave better results from
the point of view of size and shape homogeneity of the iron
oxide cores. Moreover, this procedure is more convenient for
Fig. 7 MRI images of vials containing SPIO@PAA(2), Magnevist® and Endorem® at the same concentration (∼0.85 mM), and ultrapure water,
obtained by an Artoscan (by Esaote SpA) imager at 8.5 MHz by means of a high resolution spin echo sequence: (a) T1 weighted and (b) T2 weighted
images.
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rhenium conjugation, since it strongly reduces the manipu-
lation times of the reactants containing hot rhenium isotopes.
The synthesized hybrid organic–inorganic nanocomposites
show superparamagnetic behaviour at room temperature.
Remarkably, the samples have demonstrated the capacity to
behave as MRI contrast agents similar or superior to a well-
known commercial product, i.e. Endorem®, as demonstrated
both by transverse relaxation measurements and in vitro MRI
experiments. The presented nanocomposites have thus proven
to be very interesting systems, since the capability to encapsu-
late rhenium might allow the NPs to behave as bifunctional
imaging probes, useful for both MRI and SPECT, if hot
186/188Re isotopes were used. On the other hand, the potential
of the nanocomposites to behave as theranostic agents
must be noted, since Re-containing hybrid materials could be
employed for radiotherapy, owing to the β-emission of the hot
rhenium isotopes.45 This makes fundamental the achievement
of selectivity in cancer tissues addressing. The spontaneous
tendency of NPs to accumulate in the tumour tissues (by
enhanced permeability and retention eﬀects)63 and the mag-
netic transport64 could be exploited, but functionalization of
the nanocomposites with actively targeting moieties would
also be highly advisable.65 Further investigation in this direc-
tion is under way.
In the future, eﬀorts will be devoted also to the preparation
of SPIO NPs with a suitable size for hyperthermia treat-
ments,22,66,67 thus enhancing the multifunctionality of the
hybrid organic–inorganic nanocomposite. A further possible
development towards multifunctional magnetic/luminescent/
γ-emitter materials could be provided by using, for SPIO NPs
stabilization, the recently reported ISA23-based copolymer
bearing a phenanthroline pendant in its minority part, able to
rapidly bind to Re(CO)3 fragments, aﬀording luminescent poly-
meric complexes.68
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